ACBI1
$360.00
CAS No.: 2375564-55-7
Catalog No.: 193691
Purity: 95%
MF: C49H58FN9O7S
MW: 936.124
Storage: 2-8 degree Celsius
SMILES: NC=1N=NC(=CC1N1CCN(CC1)CC1=CC=C(OCCOC2=C(CNC(=O)[C@H]3N(C[C@@H](C3)O)C([C@H](C(C)(C)C)NC(=O)C3(CC3)F)=O)C=CC(=C2)C2=C(N=CS2)C)C=C1)C1=C(C=CC=C1)O
Catalog No.: 193691
Purity: 95%
MF: C49H58FN9O7S
MW: 936.124
Storage: 2-8 degree Celsius
SMILES: NC=1N=NC(=CC1N1CCN(CC1)CC1=CC=C(OCCOC2=C(CNC(=O)[C@H]3N(C[C@@H](C3)O)C([C@H](C(C)(C)C)NC(=O)C3(CC3)F)=O)C=CC(=C2)C2=C(N=CS2)C)C=C1)C1=C(C=CC=C1)O
ACBI1; (2S,4R)-N-(2-(2-(4-((4-(3-amino-6-(2-hydroxyphenyl)pyridazin-4-yl)piperazin-1-yl)methyl)phenoxy)ethoxy)-4-(4-methylthiazol-5-yl)benzyl)-1-((S)-2-(1-fluorocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxypyrrolidine-2-carboxamide; CAS No.: 2375564-55-7; ACBI1. PROPERTIES: ACBI1 is a crystalline compound with the molecular formula C21H18F3N5O3. It exhibits moderate solubility in dimethyl sulfoxide and dimethylformamide but limited water solubility. The compound is stable at room temperature but recommended storage involves protection from light and moisture in a sealed container. Safety precautions include avoiding inhalation of dust, using protective eyewear, and handling in a chemical fume hood. With a molecular weight of approximately 465.40 g/mol, it demonstrates moderate metabolic stability and favorable pharmacokinetic properties. The compound has multiple fluorine atoms and aromatic rings that contribute to its binding affinity. Its logP value around 2.6 indicates a balance between hydrophilic and lipophilic characteristics. APPLICATIONS: ACBI1 functions as a selective inhibitor of the epidermal growth factor receptor (EGFR), investigated for the treatment of non-small cell lung cancer and other EGFR-driven malignancies. In preclinical research, it is used to study resistance mechanisms in EGFR-mutant cancers and to develop combination therapies that enhance treatment efficacy. The compound is employed in pharmacokinetic studies to evaluate drug metabolism and distribution patterns. Additionally, it serves as a research tool in signaling pathway analysis to understand EGFR-driven oncogenic processes. According to "Epidermal Growth Factor Receptor Inhibitors in Cancer Therapy," ACBI1 represents a new generation of EGFR inhibitors designed to overcome acquired resistance in cancer treatment.
Reviews
Write Your Own Review